# Merck & Co., Inc. (MRK)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/merck-and-co-inc/ JSON: https://steadybase.io/company/merck-and-co-inc.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: Merck & Co., Inc.
- Ticker: MRK (NYSE)
- SEC CIK: 0000310158
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Rahway, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: merck.com
- Investor relations: https://www.merck.com/investor-relations/
- LinkedIn: https://www.linkedin.com/company/merck
- Next earnings date: Feb 2, 2027

## Key facts

- Revenue: $65.0B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/0000310158-26-000063-index.html
- Net income: $18.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/0000310158-26-000063-index.html
- SG&A: $10.7B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/0000310158-26-000063-index.html
- Employees: 75,000 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/0000310158-26-000063-index.html
- Shares outstanding: 2,465,245,688 as of Oct 31, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/0000310158-26-000248-index.html
- Auditor: Pricewaterhousecoopers LLP, Florham Park, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm

## Business

, Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Net income | SG&A |
|---|---|---|---|
| Dec 31, 2025 | $65.0B | $18.3B | $10.7B |
| Dec 31, 2024 | $64.2B | $17.1B | $10.8B |
| Dec 31, 2023 | $60.1B | $365.0M | $10.5B |
| Dec 31, 2022 | $59.3B | $14.5B | $10.0B |
| Dec 31, 2021 | $48.7B | $13.0B | $9.6B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/merck-and-co-inc.json

## Officers and directors

- Robert M. Davis, Chairman, CEO & President. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000127/0000310158-26-000127-index.htm
- Caroline Litchfield, EVP & CFO. LinkedIn: https://www.linkedin.com/in/caroline-litchfield-4569a9a8. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000135/0000310158-26-000135-index.htm
- Gaurav K. Gupta, EVP, CIDO. LinkedIn: https://linkedin.com/in/gauravgupta9. Source: Form 3 filed Sep 1, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000225/0000310158-26-000225-index.htm
- Chirfi Guindo, EVP, Access, Policy & Comms. LinkedIn: https://linkedin.com/in/chirfi-guindo-1442b612b. Source: Form 4 filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000223/0000310158-26-000223-index.htm
- Jennifer Zachary, EVP, General Counsel. LinkedIn: https://linkedin.com/in/jennifer-zachary-6b11328. Source: Form 4 filed Aug 13, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000221/0000310158-26-000221-index.htm
- Richard R. DeLuca, EVP&Pres, Merck Animal Heallth. Source: Form 4 filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000219/0000310158-26-000219-index.htm
- David Michael Williams, EVP,Chief Info&Digital Officer. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000214/0000310158-26-000214-index.htm
- David R. Maraldo, EVP & Pres. MMD. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000215/0000310158-26-000215-index.htm
- Betty D. Larson, EVP, Chief HR Officer. LinkedIn: https://linkedin.com/in/betty-larson-3284542. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000131/0000310158-26-000131-index.htm
- Brian Foard, EVP, Specialty, Pharma, & ID. LinkedIn: https://linkedin.com/in/brian-foard-99b27626. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000125/0000310158-26-000125-index.htm
- Dalton E. Smart III, SVP Fin. - Global Controller. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000119/0000310158-26-000119-index.htm
- Johannes Jacobus Oosthuizen, EVP, Oncology & Int?l. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000121/0000310158-26-000121-index.htm
- Dalton Smart, Senior Vice President Finance, Global Controller. LinkedIn: https://linkedin.com/in/dalton-smart-cpa-mba-3b83a1198. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- David M. Williams, Executive Vice President, Chief Information and Digital Officer. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Dean Li, Executive Vice President, President, Merck Research Laboratories. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Richard R. DeLuca, Jr., Executive Vice President and President, Merck Animal Health. LinkedIn: https://linkedin.com/in/richard-deluca-86325613. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Cristal N. Downing, Chief Comm. & Public Afrs Ofcr. Source: Form 4 filed Nov 12, 2025, https://www.sec.gov/Archives/edgar/data/310158/000031015825000061/0000310158-25-000061-index.htm
- Johannes J. Oosthuizen, Senior Vice President and President Merck U.S. Human Health. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Joseph Romanelli, Senior Vice President and President MSD International Human Health. Source: 10-K filed Feb 24, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Dean Y. Li, Executive VP & President, MRL. Source: Form 4 filed May 7, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000133/0000310158-26-000133-index.htm
- Sanat Chattopadhyay, Exe V-P & Pres. MMD. Source: Form 4 filed May 1, 2026, https://www.sec.gov/Archives/edgar/data/310158/000031015826000097/0000310158-26-000097-index.htm
- Dean Li, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories. Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/310158/000119312526147704/d85708ddef14a.htm
- Thomas H. Glocer, Board member (per proxy). Source: DEF 14A filed Apr 8, 2026, https://www.sec.gov/Archives/edgar/data/310158/000119312526147704/d85708ddef14a.htm

## Recent 8-K events

- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_8k.htm
- Oct 13, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/mrk-20261009.htm
- Aug 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_8k.htm
- May 28, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465926067509/tm2615833d1_8k.htm
- May 22, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000162828026037738/mrk-20260522.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_8k.htm
- Feb 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_8k.htm
- Dec 4, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000162828025055388/mrk-20251204.htm
- Oct 30, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_8k.htm
- Sep 9, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015825000047/mrk-20250909.htm

## Insider trades (Form 4)

- Aug 13, 2026: Chirfi Guindo (EVP, Access, Policy & Comms) sold 10,000 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000223/0000310158-26-000223-index.htm
- Aug 12, 2026: Jennifer Zachary (EVP, General Counsel) sold 80,315 shares, about $10.7M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000221/0000310158-26-000221-index.htm
- Aug 12, 2026: Richard R. DeLuca (EVP&Pres, Merck Animal Heallth) sold 45,320 shares, about $5.9M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000219/0000310158-26-000219-index.htm
- Aug 6, 2026: Richard R. DeLuca (EVP&Pres, Merck Animal Heallth) sold 6,050 shares, about $788,764. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000217/0000310158-26-000217-index.htm
- Aug 6, 2026: Chirfi Guindo (EVP, Access, Policy & Comms) sold 15,000 shares, about $2.0M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000213/0000310158-26-000213-index.htm
- Aug 5, 2026: David R. Maraldo (EVP & Pres. MMD) sold 18,706 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000215/0000310158-26-000215-index.htm
- Aug 5, 2026: David Michael Williams (EVP,Chief Info&Digital Officer) sold 52,847 shares, about $6.8M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000214/0000310158-26-000214-index.htm
- Feb 12, 2026: Chirfi Guindo (Chief Marketing Officer) sold 10,000 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000052/0000310158-26-000052-index.htm
- Feb 10, 2026: Dean Y. Li (Executive VP & President, MRL) sold 10,235 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000050/0000310158-26-000050-index.htm
- Feb 9, 2026: Chirfi Guindo (Chief Marketing Officer) sold 10,000 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000048/0000310158-26-000048-index.htm
- Feb 9, 2026: Jennifer Zachary (EVP, General Counsel) sold 121,573 shares, about $14.5M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000046/0000310158-26-000046-index.htm
- Feb 6, 2026: David Michael Williams (EVP,Chief Info&Digital Officer) sold 5,000 shares, about $609,550. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000044/0000310158-26-000044-index.htm
- Feb 6, 2026: Johannes Jacobus Oosthuizen (President, U.S. Market) sold 15,000 shares, about $1.8M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000040/0000310158-26-000040-index.htm
- Feb 6, 2026: Richard R. DeLuca (EVP&Pres, Merck Animal Heallth) sold 37,685 shares, about $4.6M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000032/0000310158-26-000032-index.htm
- Feb 5, 2026: Chirfi Guindo (Chief Marketing Officer) sold 20,000 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/310158/000031015826000034/0000310158-26-000034-index.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_8k.htm
- 10-K filed Feb 24, 2026: https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- 10-Q filed Aug 7, 2026: https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm
- DEF 14A filed Apr 8, 2026: https://www.sec.gov/Archives/edgar/data/310158/000119312526147704/d85708ddef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/